European Monoclonal Antibodies Market size to cross $113 Bn by 2028

Published Date: 2022-04-28

Request a sample

European Monoclonal Antibodies Market size is projected to reach USD 113 billion by 2028, according to a latest forecast report by Graphical Research.

Expanding clinical applications of monoclonal antibodies (mAbs) in disease treatment will influence the product adoption rate across the European countries. Numerous clinical trials are being performed to identify the potential of mAb therapeutics for different conditions such as hereditary angioedema, type 1 diabetes, kidney transplantation, Alzheimer’s disease and Parkinson’s disease among others. The emergence of COVID-19 has further influenced the R&D activities across the industry. Therefore, growing development activities will positively impact the product approval rate, thereby driving the business revenue growth. Recently, in December 2021, GlaxoSmithKline plc and Vir Biotechnology, Inc. received the marketing authorisation by the European Commission (EC) for Xevudy (sotrovimab) used in the early treatment of COVID-19. Thus, extensive product pipeline with increasing R&D will benefit the market growth.

With significant increase in the development and commercialization of mAb therapeutics for the COVID-19 treatment, the industry witnessed remarkable growth. The new product launches during the pandemic to offer effective treatment has influenced the business revenues of the operating companies. Additionally, the capability of mAbs to neutralize the infection has helped in reducing the risk of mortality. Moreover, the government purchase agreements with companies for approved potential products offered growth opportunities.

The humanized monoclonal antibodies segment was valued at USD 15.5 billion revenue in 2021 attributed to increasing product launches and improved regulatory support in the region. Availability of range of humanized monoclonal antibodies approved for therapeutic applications in cancer treatment including breast cancer, lung cancer, melanoma and stomach cancer among others will contribute to the segment revenue. As some of the humanized mAbs have direct binding capability to the C-erB2 protein (HER2), these are considered as an effective treatment for the breast cancer. Thus, increasing product adoption rate with rising incidence of cancer will impel the market growth.

The infectious disease segment will grow at 13.2% CAGR during the forecast timeframe due the increasing burden of severe infectious diseases coupled with rising adoption of mAb therapeutics in disease treatment. Further, the emergence of new, previously unidentified, infectious diseases including COVID-19 has driven the development of innovative and specific monoclonal antibody therapies. The number of potential therapies in pipeline catering to the several severe infectious diseases will strengthen the industry growth.

Browse detailed statistical insights from the report, “Europe Monoclonal Antibodies Market Forecast 2028 By End-use (Hospitals, Specialty Centers), By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), Research Report, Country Outlook (Germany, UK, France, Spain, Italy, Denmark, Sweden, Poland, The Netherlands, Belgium, Romania, Czech Republic), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @

The hospitals end use segment held more than 42% market share in 2021 owing to increasing number of hospitals offerings specialty treatments with highly skilled professionals. The increasing patient visits will stimulate the demand for product in hospitals settings. Furthermore, extensive marketing efforts by the operational companies to educate healthcare professionals regarding the newly introduced mAb-based therapeutics for highly prevalent diseases including cancer will contribute the market growth. Moreover, the introduction of favorable reimbursement policies in hospitals with the government support for high-cost treatment will propel the market demand.

UK monoclonal antibodies market will expand at over 12.6% CAGR between 2022 and 2028 credited to the high incidence of cancer and autoimmune diseases. Additionally, increasing accessibility and product availability with expanding presence of leading business players in the country will benefit the domestic market. Further, rising healthcare spending and disposable income of the population influences treatment affordability for high-cost therapies, thereby contributing to the market growth.

The monoclonal antibodies in European market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2017 to 2028, for the following segments:

Europe Market, By Type

  • Fully Human
  • Humanized
  • Chimeric
  • Others

Europe Market, By Application

  • Oncology
  • Autoimmune diseases
  • Infectious diseases
  • Others

Europe Market, By End-use

  • Hospitals
  • Specialty Centers
  • Others

The above information has been provided for the following countries:

  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Denmark
    • Sweden
    • Poland
    • The Netherlands
    • Belgium
    • Romania
    • Czech Republic